SCHEMBL21859686

SCHEMBL21859686

CCCC(CC)C[C@H]1CCCN1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FDPS P14324 1/20 0.42
CYP2D6 P10635 2/20 0.42
MEN1 O00255 2/20 0.42
LMNA P02545 2/20 0.42
TP53 P04637 2/20 0.42
KMT2A Q03164 2/20 0.42
GHSR Q92847 2/20 0.42
SLC6A2 P23975 2/20 0.42
SLC6A4 P31645 2/20 0.42
SLC6A3 Q01959 2/20 0.42
ALDH1A1 P00352 1/20 0.42
CYP1A2 P05177 1/20 0.42
TSHR P16473 1/20 0.42
MLNR O43193 1/20 0.42
ABCB11 O95342 1/20 0.42
EGFR P00533 1/20 0.42
FYN P06241 1/20 0.42
CHRM2 P08172 1/20 0.42
CHRM4 P08173 1/20 0.42
HTR1A P08908 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24980421 1.00 FDPS (0.42) FDPSCYP2D6MEN1LMNATP53
SCHEMBL23844748 0.89 DPP7 (0.40) FDPSCYP2D6MEN1LMNATP53
SCHEMBL20725553 0.89 DPP7 (0.40) FDPSCYP2D6MEN1LMNATP53
SCHEMBL23844547 0.89 DPP7 (0.40) FDPSCYP2D6MEN1LMNATP53
SCHEMBL465203 0.89 DPP7 (0.40) FDPSCYP2D6MEN1LMNATP53
SCHEMBL21162747 0.83 FDPS (0.45) FDPSCYP2D6MEN1LMNATP53
SCHEMBL21064561 0.82 CYP2D6 (0.55) FDPSCYP2D6MEN1LMNATP53
SCHEMBL18595936 0.79 CYP2D6 (0.43) FDPSCYP2D6MEN1LMNATP53
SCHEMBL22193263 0.79 CYP2D6 (0.43) FDPSCYP2D6MEN1LMNATP53
SCHEMBL23717795 0.79 PRCP (0.42) FDPSCYP2D6MEN1LMNATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2020-03-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10604507-B2 Melanocortin subtype-2 receptor (MC2R) antagonists and uses thereof MC3R, MC1R, MC2R FDPS 4517/4885CYP2D6 1931/4885MEN1 644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.